Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Insulin9623 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A50180 | 35487948 | Sci Rep | Hibiscus sabdariffa extract improves hepatic steatosis, partially through IRS-1/Akt and Nrf2 signaling pathways in rats fed a high fat diet. | 2022 | Details |
| A50190 | 35484644 | Clin Mol Hepatol | Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in NAFLD mouse models using modified basket trial. | 2022 | Details |
| A50193 | 35483638 | J Control Release | Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease. | 2022 | Details |
| A50204 | 35476909 | Angiology | Atherosclerosis and Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50214 | 35471471 | Front Med | Lingguizhugan Decoction, a Chinese herbal formula, improves insulin resistance in overweight/obese subjects with non-alcoholic fatty liver disease: a translational approach. | 2022 | Details |
| A50226 | 35465068 | Gastroenterol Hepatol (N Y) | Nonalcoholic Fatty Liver Disease in Children. | 2021 | Details |
| A50231 | 35463855 | Diabetol Int | The epidemiology, clinical, biochemical, immunological and radiological features of youth onset type 2 diabetes mellitus in the state of Qatar. | 2021 | Details |
| A50239 | 35462330 | Biomed Pharmacother | Update of Indoles: Promising molecules for ameliorating metabolic diseases. | 2022 | Details |
| A50243 | 35460926 | Biomed J | Prognosis of Chronic Kidney Disease in Patients with Non-Alcoholic Fatty Liver Disease: a Northeastern Taiwan Community Medicine Research Cohort. | 2022 | Details |
| A50248 | 35457142 | Int J Mol Sci | Role of Branched-Chain Amino Acid Metabolism in Type 2 Diabetes, Obesity, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50251 | 35455663 | J Pers Med | Non-Alcoholic Fatty Liver Disease and the Risk of Diabetes Mellitus by Menopausal Status: A Nationwide Cohort Study. | 2022 | Details |
| A50259 | 35451807 | Curr Med Sci | Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice. | 2022 | Details |
| A50268 | 35449197 | Cell Death Discov | HtrA2/Omi mitigates NAFLD in high-fat-fed mice by ameliorating mitochondrial dysfunction and restoring autophagic flux. | 2022 | Details |
| A50270 | 35448550 | Metabolites | Flavin-Containing Monooxygenase 3 (FMO3) Is Critical for Dioxin-Induced Reorganization of the Gut Microbiome and Host Insulin Sensitivity. | 2022 | Details |
| A50274 | 35447548 | Biomed Pharmacother | Downregulation of hepatic fat accumulation, inflammation and fibrosis by nerolidol in purpose built western-diet-induced multiple-hit pathogenesis of NASH animal model. | 2022 | Details |
| A50284 | 35443531 | J Assoc Physicians India | Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD. | 2022 | Details |
| A50286 | 35443470 | J Assoc Physicians India | A Study of Correlation between Non Alcoholic Fatty Liver Disease and Carotid Atherosclerosis. | 2022 | Details |
| A50293 | 35442320 | Arq Gastroenterol | SHOULD ROUTINE LIVER BIOPSY BE CONSIDERED IN BARIATRIC SURGICAL PRACTICE? AN ANALYSIS OF THE LIMITATIONS OF NON-INVASIVE NAFLD MARKERS. | 2022 | Details |
| A50297 | 35440282 | Int J Circumpolar Health | Non-alcoholic fatty liver disease in patients with type 2 diabetes in Greenland: a register-based cross-sectional study. | 2022 | Details |
| A50307 | 35437302 | Panminerva Med | A nutrigenetic tool for precision dietary management of NAFLD deeming insulin resistance markers. | 2022 | Details |
| A50308 | 35436984 | Cell Death Dis | B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36. | 2022 | Details |
| A50313 | 35436113 | J Agric Food Chem | Protective Effect and Mechanism of Plant-Based Monoterpenoids in Non-alcoholic Fatty Liver Diseases. | 2022 | Details |
| A50314 | 35436057 | Egypt J Immunol | Role of Thymosin Beta 4 in the diagnosis of Nonalcoholic Fatty Liver and its relation to Metabolic Syndrome in Egyptian patients. | 2022 | Details |
| A50334 | 35430025 | J Clin Lipidol | JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. | 2022 | Details |
| A50343 | 35428219 | BMC Endocr Disord | Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes. | 2022 | Details |
| A50356 | 35420457 | Cannabis Cannabinoid Res | Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock? | 2022 | Details |
| A50359 | 35418240 | Arterioscler Thromb Vasc Biol | Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. | 2022 | Details |
| A50361 | 35417923 | Hum Mol Genet | Role of non-coding RNAs on liver metabolism and NAFLD pathogenesis. | 2022 | Details |
| A50363 | 35417465 | PLoS One | The regulation of HBP1, SIRT1, and SREBP-1c genes and the related microRNAs in non-alcoholic fatty liver rats: The association with the folic acid anti-steatosis. | 2022 | Details |
| A50365 | 35416741 | Scand J Clin Lab Invest | Nonalcoholic fatty liver disease and its prognosis associates with shorter leucocyte telomeres in a 21-year follow-up study. | 2022 | Details |
| A50366 | 35416649 | J Agric Food Chem | Pterostilbene and Its Derivative 3'-Hydroxypterostilbene Ameliorated Nonalcoholic Fatty Liver Disease Through Synergistic Modulation of the Gut Microbiota and SIRT1/AMPK Signaling Pathway. | 2022 | Details |
| A50377 | 35412016 | Clin Obes | The impact of health status, diet and lifestyle on non-alcoholic fatty liver disease: Narrative review. | 2022 | Details |
| A50381 | 35410857 | Turk J Gastroenterol | Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A50384 | 35409319 | Int J Mol Sci | Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk. | 2022 | Details |
| A50386 | 35409028 | Int J Mol Sci | SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50391 | 35407014 | Foods | Tilapia-Head Chondroitin Sulfate Protects against Nonalcoholic Fatty Liver Disease via Modulating the Gut-Liver Axis in High-Fat-Diet-Fed C57BL/6 Mice. | 2022 | Details |
| A50392 | 35406736 | Cells | Multi-Omics Approach Reveals Dysregulation of Protein Phosphorylation Correlated with Lipid Metabolism in Mouse Non-Alcoholic Fatty Liver. | 2022 | Details |
| A50394 | 35406631 | Cells | Psoralen Suppresses Lipid Deposition by Alleviating Insulin Resistance and Promoting Autophagy in Oleate-Induced L02 Cells. | 2022 | Details |
| A50395 | 35406066 | Nutrients | Amino Acid-Related Metabolic Signature in Obese Children and Adolescents. | 2022 | Details |
| A50404 | 35403438 | Am J Physiol Endocrinol Metab | Loss of low-molecular-weight protein tyrosine phosphatase shows limited improvement in glucose tolerance but causes mild cardiac hypertrophy in mice. | 2022 | Details |
| A50411 | 35400330 | Endocr Metab Immune Disord Drug Targets | Literature Review on the Use of Herbal Extracts in the Treatment of Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A50412 | 35400251 | Crit Rev Food Sci Nutr | Can omega-3 fatty acids be beneficial in pediatric NAFLD? A systematic review and meta-analysis. | 2022 | Details |
| A50419 | 35398502 | J Ethnopharmacol | Integrating metabolomics and network pharmacology to reveal the mechanisms of Delphinium brunonianum extract against nonalcoholic steatohepatitis. | 2022 | Details |
| A50427 | 35396116 | Endocrinol Diabetes Nutr (Engl Ed) | Prevalence and predictors of non-alcoholic steatohepatitis in patients with morbid obesity. | 2022 | Details |
| A50435 | 35393310 | BMJ Open | Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV. | 2022 | Details |
| A50436 | 35392825 | BMC Gastroenterol | Steroid-mediated liver steatosis is CD1d-dependent, while steroid-induced liver necrosis, inflammation, and metabolic changes are CD1d-independent. | 2022 | Details |
| A50447 | 35387749 | Eur J Intern Med | Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes. | 2022 | Details |
| A50456 | 35384023 | Clin Endocrinol (Oxf) | Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome. | 2022 | Details |
| A50463 | 35381388 | Mol Metab | Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism. | 2022 | Details |
| A50468 | 35378329 | Mol Metab | Hepatocyte-specific activity of TSC22D4 triggers progressive NAFLD by impairing mitochondrial function. | 2022 | Details |
| A50478 | 35370963 | Front Endocrinol (Lausanne) | The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders. | 2022 | Details |
| A50499 | 35363908 | Hepatology | Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? | 2022 | Details |
| A50511 | 35358477 | Biochem Pharmacol | Valdecoxib attenuates lipid-induced hepatic steatosis through autophagy-mediated suppression of endoplasmic reticulum stress. | 2022 | Details |
| A50512 | 35357518 | Naunyn Schmiedebergs Arch Pharmacol | Phytochemicals targeting NAFLD through modulating the dual function of forkhead box O1 (FOXO1) transcription factor signaling pathways. | 2022 | Details |
| A50513 | 35357066 | Liver Int | Impact of a Mediterranean diet on hepatic and metabolic outcomes in non-alcoholic fatty liver disease: The MEDINA randomised controlled trial. | 2022 | Details |
| A50519 | 35354928 | Pediatr Res | LncOb rs10487505 variant is associated with leptin levels in pediatric non-alcoholic fatty liver disease. | 2022 | Details |
| A50523 | 35354619 | BMJ Open | Validation of type 2 diabetes subgroups by simple clinical parameters: a retrospective cohort study of NHANES data from 1999 to 2014. | 2022 | Details |
| A50543 | 35347118 | Cell Death Dis | Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance. | 2022 | Details |
| A50562 | 35339664 | Diabetes Metab | The triglycerides and glucose (TyG) index: A new marker associated with nonalcoholic steatohepatitis (NASH) in obese patients. | 2022 | Details |
| A50563 | 35339509 | Life Sci | Autophagic dysfunction in the liver enhances the expression of insoluble nuclear proteins 14-3-3ζ and importin α4. | 2022 | Details |
| A50566 | 35338494 | J Food Biochem | Zingerone ameliorates non-alcoholic fatty liver disease in rats by activating AMPK. | 2022 | Details |
| A50576 | 35334784 | Nutrients | Added Fructose in Non-Alcoholic Fatty Liver Disease and in Metabolic Syndrome: A Narrative Review. | 2022 | Details |
| A50579 | 35333917 | J Clin Endocrinol Metab | A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now. | 2022 | Details |
| A50584 | 35332833 | Postgrad Med | Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population. | 2022 | Details |
| A50586 | 35332431 | Intern Emerg Med | Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. | 2022 | Details |
| A50588 | 35332111 | J Obes Metab Syndr | Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50590 | 35331900 | J Nutr Biochem | Intermittent fasting, high-intensity interval training, or a combination of both have beneficial effects in obese mice with nonalcoholic fatty liver disease. | 2022 | Details |
| A50602 | 35328503 | Int J Mol Sci | The Endocannabinoid System and Physical Activity-A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders. | 2022 | Details |
| A50611 | 35326230 | Antioxidants (Basel) | Combination Effects of Metformin and a Mixture of Lemon Balm and Dandelion on High-Fat Diet-Induced Metabolic Alterations in Mice. | 2022 | Details |
| A50622 | 35323681 | Metabolites | Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH. | 2022 | Details |
| A50627 | 35322435 | J Food Biochem | Chia seeds and chemical-elicited sprouts supplementation ameliorates insulin resistance, dyslipidemia, and hepatic steatosis in obese rats. | 2022 | Details |
| A50630 | 35321843 | Clin Res Hepatol Gastroenterol | Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2022 | Details |
| A50632 | 35320000 | Sci Transl Med | Hepatic IRF3 fuels dysglycemia in obesity through direct regulation of Ppp2r1b. | 2022 | Details |
| A50637 | 35318963 | J Endocrinol | AKR1D1 knockout mice develop a sex-dependent metabolic phenotype. | 2022 | Details |
| A50638 | 35318738 | Phytother Res | Effect of rosemary leaf powder with weight loss diet on lipid profile, glycemic status, and liver enzymes in patients with nonalcoholic fatty liver disease: A randomized, double-blind clinical trial. | 2022 | Details |
| A50651 | 35314476 | BMJ Open | Role of age, gender and ethnicity in the association between visceral adiposity index and non-alcoholic fatty liver disease among US adults (NHANES 2003-2018): cross-sectional study. | 2022 | Details |
| A50653 | 35313531 | Metabol Open | Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. | 2022 | Details |
| A50656 | 35312185 | Hepatol Commun | Transcriptomic profiling of a multiethnic pediatric NAFLD cohort reveals genes and pathways associated with disease. | 2022 | Details |
| A50657 | 35311933 | Am J Clin Pathol | Clinical, Laboratory, and Histologic Correlates of Serum Antinuclear Antibody in Hispanic Pediatric Patients With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50668 | 35308224 | Front Pharmacol | Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50672 | 35307033 | BMC Med | Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study). | 2022 | Details |
| A50684 | 35303270 | J Endocrinol Invest | Non-alcoholic fatty liver disease through the female lifespan: the role of sex hormones. | 2022 | Details |
| A50689 | 35301333 | Nat Commun | Autophagy impairment in liver CD11c+ cells promotes non-alcoholic fatty liver disease through production of IL-23. | 2022 | Details |
| A50690 | 35300452 | Indian J Endocrinol Metab | One-Hour Postload Plasma Glucose in Obese Indian Adults with Nonalcoholic Fatty Liver Disease: An Observational Study from North India. | 2022 | Details |
| A50700 | 35295576 | Front Physiol | Polyene Phosphatidylcholine Ameliorates High Fat Diet-Induced Non-alcoholic Fatty Liver Disease via Remodeling Metabolism and Inflammation. | 2022 | Details |
| A50710 | 35291351 | Med (N Y) | Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings. | 2021 | Details |
| A50713 | 35290413 | PLoS One | Abelmoschus esculentus subfractions ameliorate hepatic lipogenesis and lipid uptake via regulating dipeptidyl peptidase-4-With improving insulin resistance. | 2022 | Details |
| A50733 | 35283810 | Front Microbiol | Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction. | 2022 | Details |
| A50736 | 35283265 | Diabetes Res Clin Pract | Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. | 2022 | Details |
| A50739 | 35283114 | Gastroenterology | Postprandial Plasma Lipidomics Reveal Specific Alteration of Hepatic-derived Diacylglycerols in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50741 | 35282455 | Front Endocrinol (Lausanne) | Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2022 | Details |
| A50743 | 35280896 | Front Med (Lausanne) | Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study. | 2022 | Details |
| A50764 | 35276001 | J Clin Endocrinol Metab | Endotoxin Biomarkers Are Associated With Adiposity and Cardiometabolic Risk Across 6 Years of Follow-up in Youth. | 2022 | Details |
| A50769 | 35273160 | Nat Commun | Deep proteomic profiling unveils arylsulfatase A as a non-alcoholic steatohepatitis inducible hepatokine and regulator of glycemic control. | 2022 | Details |
| A50770 | 35272243 | Phytomedicine | Therapeutic effect and mechanism of polysaccharides from Anoectochilus Roxburghii (Wall.) Lindl. in diet-induced obesity. | 2022 | Details |
| A50776 | 35269912 | Int J Mol Sci | Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. | 2022 | Details |
| A50778 | 35269812 | Int J Mol Sci | Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A50783 | 35268466 | J Clin Med | The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2022 | Details |
| A50788 | 35266164 | Aliment Pharmacol Ther | Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know. | 2022 | Details |
| A50791 | 35265044 | Front Endocrinol (Lausanne) | Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction. | 2022 | Details |